Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says

Vera Therapeutics (NASDAQ:VERA) had its price target upped by equities research analysts at Bank of America from $65.00 to $70.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price target would indicate a potential upside of 66.15% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research note on Friday, May 15th. Finally, Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a report on Wednesday, March 11th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $78.40.

Vera Therapeutics Trading Up 5.0%

Shares of NASDAQ:VERA traded up $2.00 during trading on Tuesday, hitting $42.13. The company had a trading volume of 3,681,278 shares, compared to its average volume of 1,293,429. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -7.66 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The company has a fifty day simple moving average of $36.19 and a two-hundred day simple moving average of $41.24. Vera Therapeutics has a one year low of $19.07 and a one year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the company earned ($0.81) earnings per share. As a group, equities analysts forecast that Vera Therapeutics will post -6.23 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 59,951 shares of company stock valued at $2,392,387 over the last three months. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently made changes to their positions in VERA. GAMMA Investing LLC increased its stake in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Optimize Financial Inc lifted its stake in Vera Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares in the last quarter. Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 5.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after buying an additional 290 shares in the last quarter. Intech Investment Management LLC lifted its stake in Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after buying an additional 424 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Vera Therapeutics by 2.0% in the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.